As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kalaris Therapeutics, Inc. The largest reported stake is Samsara BioCapital, L.P.'s, at 54.2%. 6 filings are on record since July 29, 2025 (Schedule 13D/A, May 22, 2026).
Sell to companies like Kalaris Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 1,355,119 · Sole dispositive: 0 · Shared dispositive: 1,355,119 · SCHEDULE 13G, 2026-10-26
- · Reporting person: Samsara BioCapital, L.P. · Sole voting: 0 · Shared voting: 10,657,028 · Sole dispositive: 0 · Shared dispositive: 10,657,028 · SCHEDULE 13D/A, 2026-05-22
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 1,300,000 · Sole dispositive: 0 · Shared dispositive: 1,300,000 · SCHEDULE 13G, 2026-02-17
- · Holder: Samsara BioCapital, L.P. · Percent: 56.5% · SCHEDULE 13D/A
- · Holder: Samsara BioCapital, L.P. · Percent: 56.5% · SCHEDULE 13D/A
Kalaris Therapeutics, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-29. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Samsara BioCapital, L.P. | 54.2% | 10,657,028 | SCHEDULE 13D/A, 2026-05-22 | 2026-05-20 |
| RTW Investments, LP | 5.7% | 1,300,000 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Coastlands Capital LP | 5.69% | 1,355,119 | SCHEDULE 13G, 2026-10-26 | 2026-10-19 |
| Invus Public Equities, L.P. | 1.5% | 282,586 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
Holding shares or following this stake? See who's behind Kalaris Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Kalaris Therapeutics, Inc. and the records around it.
Kalaris Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Kalaris Therapeutics, Inc.
Get an email when Kalaris Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kalaris Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kalaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kalaris Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 0 | 10,657,028 | 0 | 10,657,028 | SCHEDULE 13D/A, 2026-05-22 |
| Samsara BioCapital GP, LLC | 0 | 10,671,965 | 0 | 10,671,965 | SCHEDULE 13D/A, 2026-05-22 |
| Samsara Opportunity Fund, L.P. | 0 | 2,224,147 | 0 | 2,224,147 | SCHEDULE 13D/A, 2026-05-22 |
| Samsara Opportunity Fund GP, LLC | 0 | 2,224,147 | 0 | 2,224,147 | SCHEDULE 13D/A, 2026-05-22 |
| Srinivas Akkaraju | 8,000 | 12,900,583 | 8,000 | 12,900,583 | SCHEDULE 13D/A, 2026-05-22 |
| RTW Investments, LP | 0 | 1,300,000 | 0 | 1,300,000 | SCHEDULE 13G, 2026-02-17 |
| Roderick Wong | 0 | 1,300,000 | 0 | 1,300,000 | SCHEDULE 13G, 2026-02-17 |
| Coastlands Capital LP | 0 | 1,355,119 | 0 | 1,355,119 | SCHEDULE 13G, 2026-10-26 |
| Coastlands Capital Partners LP | 0 | 1,355,119 | 0 | 1,355,119 | SCHEDULE 13G, 2026-10-26 |
| Coastlands Capital GP LLC | 0 | 1,355,119 | 0 | 1,355,119 | SCHEDULE 13G, 2026-10-26 |
| Coastlands Capital LLC | 0 | 1,355,119 | 0 | 1,355,119 | SCHEDULE 13G, 2026-10-26 |
| Matthew D. Perry | 0 | 1,355,119 | 0 | 1,355,119 | SCHEDULE 13G, 2026-10-26 |
The latest filing identifies Kalaris Therapeutics, Inc. by CUSIP 482929106 and gives its principal executive office as 400 Connell Drive, Suite 5500, Berkeley Heights, NJ 07922 (SCHEDULE 13G, 2026-10-26).
Source of funds (Item 3)
Item 3 of the Statement is hereby amended and supplemented as follows: On May 20, 2026, Samsara Opportunity Fund purchased 244,300 shares of common stock from Samsara LP in a private sale for $4.83 per share, or an aggregate purchase price of $1,179,969.00. These shares represented shares held by Samsara LP for the exclusive benefit of limited partners who had redeemed their respective interests in Samsara LP and in which neither Samsara GP nor Dr. Akkaraju had any economic interest.Samsara BioCapital, L.P., SCHEDULE 13D/A, 2026-05-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | Invus Public Equities, L.P. | 1.5% | SCHEDULE 13G/A |
| 2025-12-22 | Samsara BioCapital, L.P. | 56.5% | SCHEDULE 13D/A |
| 2026-02-17 | RTW Investments, LP | 5.7% | SCHEDULE 13G |
| 2026-02-17 | Samsara BioCapital, L.P. | 56.5% | SCHEDULE 13D/A |
| 2026-05-22 | Samsara BioCapital, L.P. | 54.2% | SCHEDULE 13D/A |
| 2026-10-26 | Coastlands Capital LP | 5.69% | SCHEDULE 13G |
Questions about who owns Kalaris Therapeutics, Inc.
Who owns Kalaris Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Kalaris Therapeutics, Inc.: Samsara BioCapital, L.P. (54.2%, Schedule 13D/A, filed 2026-05-22), RTW Investments, LP (5.7%, Schedule 13G, filed 2026-02-17) and Coastlands Capital LP (5.69%, Schedule 13G, filed 2026-10-26).
Who are the largest shareholders of Kalaris Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kalaris Therapeutics, Inc. on this page are Samsara BioCapital, L.P. (54.2%), RTW Investments, LP (5.7%) and Coastlands Capital LP (5.69%).
When did Samsara BioCapital, L.P. buy into Kalaris Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Samsara BioCapital, L.P. on this page is the Schedule 13D/A, filed 2025-12-22, reporting 56.5%; its latest, Schedule 13D/A filed 2026-05-22, reports 54.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kalaris Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 20, 2026 | Leadership change: Liisa Bayko appointed, Chief Financial Officer, and 2 more | — | Leadership changes | Source |
| July 6, 2026 | Leadership change: Laurie Keating appointed, Director, and 1 more | — | Leadership changes | Source |
| April 10, 2026 | Leadership change: Matthew Gall departs, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Kalaris Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.